Molecular adsorbents recirculating system in patients with severe liver failure. Experience of a single Romanian centre
- PMID: 19795025
Molecular adsorbents recirculating system in patients with severe liver failure. Experience of a single Romanian centre
Abstract
Aim: This is a retrospective, observational study regarding the experience of the Fundeni Clinical Institute in the application of the Molecular Adsorbents Recirculating System in patients with liver failure.
Method: From January 2002 until December 2007, we performed 50 MARS sessions in 27 patients, mean age 38.96+/-19.58 years. The etiology of liver failure was as follows: acute liver failure (ALF) in 7 patients, acute-on-chronic liver failure (AoCLF) in 10 patients, post-liver transplantation in 8 patients, and post-hepatectomy in 2 patients.
Results: We noticed the following clinical effects: improvement in general condition, in neurological status, marked regression of jaundice and pruritus, improvement in renal function and in hemodynamic status. Of the 7 patients with ALF, 3 patients (42.8 %) survived due to their own liver recovery. Only 2 patients (20%) with AoCLF survived. In this group, one patient was transplanted, one patient is alive, and the mean survival of the remaining patients was 24.5+/-34.6 days. In the post-liver transplantation group, one patient was retransplanted, one patient is alive and the mean survival of the other 6 patients was 28.5+/-39.8 days. One patient with post-hepatectomy liver failure presented spontaneous liver recovery.
Conclusion: MARS therapy was well tolerated by the patients. MARS therapy efficiently removed water soluble and albumin-bound toxins. The unfavorable prognostic factors were the association with multi organ failure and sepsis.
Similar articles
-
The effect of molecular adsorbent recirculating system treatment on survival, native liver recovery, and need for liver transplantation in acute liver failure patients.Transpl Int. 2008 Sep;21(9):857-66. doi: 10.1111/j.1432-2277.2008.00698.x. Epub 2008 May 29. Transpl Int. 2008. PMID: 18510596 Clinical Trial.
-
Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation -- a pilot study.Liver Int. 2005 Aug;25(4):740-5. doi: 10.1111/j.1478-3231.2005.01074.x. Liver Int. 2005. PMID: 15998424 Clinical Trial.
-
[The treatment of molecular adsorbents recirculating system artificial liver in severe liver failure patients with multiple organ dysfunction syndrome].Zhonghua Gan Zang Bing Za Zhi. 2003 Aug;11(8):455-7. Zhonghua Gan Zang Bing Za Zhi. 2003. PMID: 12939172 Chinese.
-
Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis.Liver Transpl. 2004 Sep;10(9):1099-106. doi: 10.1002/lt.20139. Liver Transpl. 2004. PMID: 15349999 Review.
-
Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure.J Am Soc Nephrol. 2001 Feb;12 Suppl 17:S75-82. J Am Soc Nephrol. 2001. PMID: 11251037 Review.
Cited by
-
Role of liver support systems in the management of post hepatectomy liver failure: A systematic review of the literature.Ann Hepatobiliary Pancreat Surg. 2021 May 31;25(2):171-178. doi: 10.14701/ahbps.2021.25.2.171. Ann Hepatobiliary Pancreat Surg. 2021. PMID: 34053919 Free PMC article. Review.
-
Artificial liver support systems: what is new over the last decade?Ann Intensive Care. 2018 Nov 15;8(1):109. doi: 10.1186/s13613-018-0453-z. Ann Intensive Care. 2018. PMID: 30443736 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous